Compare NXL & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXL | ALUR |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 15.4M |
| IPO Year | 2022 | N/A |
| Metric | NXL | ALUR |
|---|---|---|
| Price | $0.81 | $1.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $9.25 |
| AVG Volume (30 Days) | ★ 118.5K | 113.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,931.00 | ★ $17,208,000.00 |
| Revenue This Year | $38.28 | N/A |
| Revenue Next Year | $185.71 | $9.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $1.02 |
| 52 Week High | $4.09 | $16.81 |
| Indicator | NXL | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.04 | 45.33 |
| Support Level | $0.80 | $1.46 |
| Resistance Level | $1.01 | $1.71 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.73 | 38.47 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.